JP2024524614A - Asgpr細胞表面受容体結合化合物及びコンジュゲート - Google Patents
Asgpr細胞表面受容体結合化合物及びコンジュゲート Download PDFInfo
- Publication number
- JP2024524614A JP2024524614A JP2024501119A JP2024501119A JP2024524614A JP 2024524614 A JP2024524614 A JP 2024524614A JP 2024501119 A JP2024501119 A JP 2024501119A JP 2024501119 A JP2024501119 A JP 2024501119A JP 2024524614 A JP2024524614 A JP 2024524614A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- linker
- antibody
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221918P | 2021-07-14 | 2021-07-14 | |
| US63/221,918 | 2021-07-14 | ||
| PCT/US2022/037227 WO2023288033A1 (en) | 2021-07-14 | 2022-07-14 | Asgpr cell surface receptor binding compounds and conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524614A true JP2024524614A (ja) | 2024-07-05 |
| JP2024524614A5 JP2024524614A5 (cg-RX-API-DMAC7.html) | 2025-07-23 |
Family
ID=82786913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024501119A Pending JP2024524614A (ja) | 2021-07-14 | 2022-07-14 | Asgpr細胞表面受容体結合化合物及びコンジュゲート |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12258332B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4370157A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024524614A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240036604A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117957020A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022310356A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226269A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023288033A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022009419A (es) | 2020-01-31 | 2022-08-25 | Avilar Therapeutics Inc | Compuestos de union al asgpr para la degradacion de proteinas extracelulares. |
| EP4651904A1 (en) | 2023-01-18 | 2025-11-26 | Lycia Therapeutics, Inc. | Lysosomal targeting bifunctional molecules for degradation of autoantibodies |
| AU2024208960A1 (en) | 2023-01-18 | 2025-07-24 | Lycia Therapeutics, Inc. | Asgpr binding compounds and conjugates |
| EP4651901A1 (en) | 2023-01-18 | 2025-11-26 | Lycia Therapeutics, Inc. | Cycling lysosomal targeting antibody conjugates |
| WO2024167900A2 (en) * | 2023-02-06 | 2024-08-15 | Biohaven Therapeutics Ltd. | Bifunctional molecules to target degradation of tumor necrosis factor |
| CN121866074A (zh) | 2023-08-09 | 2026-04-14 | 利西亚治疗公司 | 用于降解肌肉特异性激酶自身抗体的溶酶体靶向双官能分子 |
| CN116854754B (zh) | 2023-09-01 | 2023-12-12 | 北京悦康科创医药科技股份有限公司 | 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物 |
| TW202516008A (zh) * | 2023-09-27 | 2025-04-16 | 大陸商上海拓界生物醫藥科技有限公司 | 含三唑基化合物、製備方法及用途 |
| WO2025199666A1 (en) * | 2024-03-25 | 2025-10-02 | Canwell Biotech Limited | Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof |
| TW202602932A (zh) | 2024-03-28 | 2026-01-16 | 美商萊西亞醫療公司 | 用於降解甲狀腺刺激荷爾蒙受體自體抗體之胞溶體靶向雙功能分子 |
| WO2025252118A1 (zh) * | 2024-06-06 | 2025-12-11 | 苏州瑞博生物技术股份有限公司 | 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途 |
| WO2026015664A1 (en) | 2024-07-10 | 2026-01-15 | Lycia Therapeutics, Inc. | Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige) |
| US12685782B2 (en) | 2024-07-31 | 2026-07-21 | Biohaven Therapeutics Ltd. | Bifunctional degraders for the treatment of Graves' disease |
| WO2026120177A1 (en) | 2024-12-06 | 2026-06-11 | Ascendis Pharma A/S | Novel long-acting degrader conjugates |
| CN120285222B (zh) * | 2025-04-15 | 2025-11-18 | 上海交通大学 | 一种靶向肝脏的药物靶向递送系统及其治疗和/或辅助治疗代谢相关脂肪性肝病的药物 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| AU2752892A (en) | 1991-09-26 | 1993-04-27 | Oklahoma Medical Research Foundation | Fusion proteins targeted to lysosomes, for the treatment of aids |
| GB9323429D0 (en) | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
| DK129293D0 (da) | 1993-11-16 | 1993-11-16 | Carlsberg Lab | Carbonhydratholdige forbindelser, der kan binde sig til carbonhydratbindende receptorer |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US20020168761A1 (en) | 2000-01-24 | 2002-11-14 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| CA2318981A1 (en) | 1998-02-09 | 1999-08-12 | Genzyme Corporation | Nucleic acid delivery vehicles |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| AU770340B2 (en) | 1998-10-08 | 2004-02-19 | Biorion Technologies B.V. | Peptide-based carrier devices for stellate cells |
| US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| WO2001050127A2 (en) | 1999-12-30 | 2001-07-12 | 7Tm Pharma | Screening using biological target molecules with metal-ion binding sites |
| US20040009907A1 (en) | 2001-02-26 | 2004-01-15 | Alsobrook John P. | Proteins and nucleic acids encoding same |
| WO2001080883A1 (en) | 2000-04-26 | 2001-11-01 | Elusys Therapeutics, Inc. | Bispecific molecules and uses thereof |
| DE10138935B4 (de) * | 2000-08-11 | 2007-08-02 | Kotobuki Pharmaceutical Co., Ltd, , Hanishina | Synthetische Verbindungen vom Nicht-Mucintyp oder ihre mit einem Träger konjugierten Verbindungen, unter deren Verwendung hergestellte monoclonale Antikörper, diese umfassende Antitumormittel Immunstimulantien und Mittel gegen das humane Immundefizienzvirus |
| NZ524980A (en) | 2000-09-01 | 2005-10-28 | Biogen Idec Inc | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications |
| ES2404689T3 (es) | 2001-04-05 | 2013-05-28 | The Johns Hopkins University | Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2 |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| EP2292273A3 (en) | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| US20050191309A1 (en) | 2002-05-06 | 2005-09-01 | Kakkis Emil D. | Induction of antigen specific immunologic tolerance |
| ES2438008T3 (es) | 2002-05-06 | 2014-01-15 | Endocyte, Inc. | Agentes de formación de imágenes dirigidos a vitaminas |
| US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| PT1628987E (pt) | 2003-05-20 | 2009-10-29 | Pharmaxis Pty Ltd | Compostos manose-6-fosfonato para o tratamento de doenças inflamatórias |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| GB0423405D0 (en) | 2004-10-21 | 2004-11-24 | Novartis Ag | Organic compounds |
| JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
| EP1745802A1 (en) | 2005-07-20 | 2007-01-24 | Kreatech Biotechnology B.V. | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
| WO2008020827A2 (en) | 2005-08-01 | 2008-02-21 | Biogen Idec Ma Inc. | Altered polypeptides, immunoconjugates thereof, and methods related thereto |
| US20070104648A1 (en) | 2005-11-09 | 2007-05-10 | Glyconix Corporation | Compositions, methods of preparing amino acids, and nuclear magnetic resonance spectroscopy |
| EP2009990B1 (en) | 2006-04-07 | 2016-09-21 | The Board of Regents of The University of Texas System | Methods and compositions related to adenoassociated virus-phage particles |
| US20080057072A1 (en) | 2006-08-31 | 2008-03-06 | Alcon Manufacturing, Ltd. | Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders |
| JP5244810B2 (ja) | 2006-11-10 | 2013-07-24 | カラ セラピューティクス インコーポレイテッド | 合成ペプチドアミド |
| WO2008089339A2 (en) | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
| WO2008156655A2 (en) | 2007-06-15 | 2008-12-24 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
| JP5366940B2 (ja) | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
| JP5675619B2 (ja) | 2008-09-17 | 2015-02-25 | エンドサイト, インク.Endocyte, Inc. | 葉酸拮抗薬の葉酸受容体結合性コンジュゲート |
| GB0817891D0 (en) | 2008-09-30 | 2008-11-05 | Medical Res Council | Antibodies against il-25 |
| EP3608330B1 (en) | 2008-12-16 | 2022-11-09 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
| US20110275576A1 (en) * | 2009-01-06 | 2011-11-10 | Utah State University | Carbohydrate-Cyclopamine Conjugates as Anticancer Agents |
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| WO2010108048A2 (en) | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
| JP2012525369A (ja) | 2009-04-28 | 2012-10-22 | ファーマキシス リミテッド | 創傷および線維性障害の治療のためのホスホテトラヒドロピラン化合物 |
| EP2448600B1 (en) | 2009-07-03 | 2016-03-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| WO2011038234A2 (en) | 2009-09-24 | 2011-03-31 | University Of Louisville Research Foundation, Inc. | Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions |
| FR2952372B1 (fr) | 2009-11-10 | 2012-03-23 | Centre Nat Rech Scient | Nouveaux derives de mannopyranoside ayant une activite anticancereuse |
| EP2343081A1 (en) | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
| CN105777907B (zh) | 2010-02-24 | 2020-03-17 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| FR2960153B1 (fr) | 2010-05-20 | 2012-08-17 | Centre Nat Rech Scient | Nouveaux bras autoreactifs et prodrogues les comprenant |
| SG186451A1 (en) | 2010-07-12 | 2013-01-30 | Covx Technologies Ireland Ltd | Multifunctional antibody conjugates |
| US20120121592A1 (en) | 2010-10-13 | 2012-05-17 | Baylor Research Institute | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells |
| LT2714752T (lt) | 2011-05-27 | 2018-03-12 | Amicus Therapeutics, Inc. | Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui |
| SG10201704846VA (en) | 2012-03-14 | 2017-07-28 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| WO2014082080A2 (en) | 2012-11-26 | 2014-05-30 | Callidus Biopharma, Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
| WO2014089209A2 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| JP2016514096A (ja) | 2013-02-20 | 2016-05-19 | バレリオン セラピューティクス, エルエルシー | ポンぺ病の処置のための方法および組成物 |
| WO2014178878A1 (en) | 2013-05-03 | 2014-11-06 | Yale University | Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
| US9943604B2 (en) * | 2013-09-20 | 2018-04-17 | Ionis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
| WO2015069587A2 (en) | 2013-11-06 | 2015-05-14 | Merck Sharp & Dohme Corp. | Peptide containing conjugates for dual molecular delivery of oligonucleotides |
| CA2946064C (en) * | 2014-02-21 | 2023-09-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Glycotargeting therapeutics |
| HUE061339T2 (hu) | 2014-03-19 | 2023-06-28 | Genzyme Corp | Targetáló csoportok helyspecifikus glikotechnikai átalakítása |
| RU2696490C2 (ru) | 2014-05-19 | 2019-08-02 | Пфайзер Инк. | Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR |
| WO2015191934A2 (en) | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
| WO2016025519A1 (en) | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| US20170290806A1 (en) | 2014-09-08 | 2017-10-12 | Temple University-Of The Commonwealth System Of Higher Education | PCSK9 Inhibitors and Methods of Use Thereof |
| PL3204425T3 (pl) | 2014-10-09 | 2021-03-08 | Genzyme Corporation | Glikomodyfikowane koniugaty przeciwciał z lekami |
| US20160166679A1 (en) | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
| JP6993958B2 (ja) | 2015-07-06 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性抗原結合分子およびその使用 |
| BR112018003179A2 (pt) | 2015-08-20 | 2018-09-25 | Albumedix As | conjugados e variantes de albumina |
| FR3041345B1 (fr) | 2015-09-18 | 2019-06-14 | Nanomedsyn | Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant |
| EP4477269A3 (en) | 2015-09-20 | 2025-03-19 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| WO2017096164A1 (en) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
| MY207684A (en) | 2015-12-08 | 2025-03-12 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| HRP20231451T1 (hr) | 2016-02-05 | 2024-03-01 | Emory University | Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu |
| KR20180104148A (ko) | 2016-02-05 | 2018-09-19 | 젠맵 에이/에스 | 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자 |
| JP7100629B2 (ja) | 2016-06-09 | 2022-07-13 | セントレ・ナショナル・デ・ラ・レシェルシェ・サイエンティフィーク | 化学修飾されたカプシドを有するraav |
| KR102085798B1 (ko) | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
| AU2018281280B2 (en) | 2017-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| CA3134765A1 (en) | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
| CA3134610A1 (en) | 2018-04-09 | 2019-10-17 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| EP3873486A4 (en) * | 2018-11-02 | 2022-10-19 | Arbutus Biopharma Corporation | Bivalent targeted conjugates |
| EP3897747A4 (en) | 2018-12-19 | 2022-12-07 | The Board of Trustees of the Leland Stanford Junior University | BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| GB201908108D0 (en) | 2019-06-06 | 2019-07-24 | King S College London | Product |
| CA3143995A1 (en) | 2019-06-21 | 2020-12-24 | Single Cell Technology, Inc. | Anti-tigit antibodies |
| EP3997214B1 (en) | 2019-07-11 | 2023-08-02 | Centre National de la Recherche Scientifique | Chemically-modified adeno-associated virus |
| US20250269043A1 (en) | 2019-10-10 | 2025-08-28 | Yale University | Targeted bifunctional degraders |
| US20240342293A1 (en) | 2019-10-10 | 2024-10-17 | Yale University | Engineered antibodies as molecular degraders through cellular receptors |
| WO2021119325A1 (en) * | 2019-12-12 | 2021-06-17 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| EP4087584A4 (en) | 2020-01-10 | 2024-08-28 | Lycia Therapeutics, Inc. | Cell surface receptor binding compounds and conjugates |
| MX2022009419A (es) | 2020-01-31 | 2022-08-25 | Avilar Therapeutics Inc | Compuestos de union al asgpr para la degradacion de proteinas extracelulares. |
| EP4100064A1 (en) | 2020-02-07 | 2022-12-14 | Novartis AG | Targeted plasma protein degradation |
| EP4168410A1 (en) | 2020-06-22 | 2023-04-26 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methotrexate analogs and methods of use |
| US20230226214A1 (en) | 2020-06-24 | 2023-07-20 | Lycia Therapeutics, Inc. | Bifunctional bridging compositions for viral transduction |
| EP4171658A4 (en) | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | Modified viral compositions for viral transduction |
| CN113943288A (zh) | 2020-07-17 | 2022-01-18 | 微境生物医药科技(上海)有限公司 | 5,6-二氢吡嗪并[2,3-c]异喹啉化合物 |
| WO2022035997A1 (en) | 2020-08-11 | 2022-02-17 | Avilar Therapeutics, Inc. | In vivo assembly of asgpr binding therapeutics |
| EP4274619A4 (en) | 2021-01-08 | 2025-09-24 | Lycia Therapeutics Inc | BIFUNCTIONAL FOLATE RECEPTOR-BINDING COMPOUNDS |
| EP4281115A1 (en) | 2021-01-19 | 2023-11-29 | Novartis AG | Degradation of extracellular targets |
| BR112023016690A2 (pt) | 2021-02-22 | 2023-11-14 | Univ Yale | Degradadores bifuncionais direcionados e métodos usando os mesmos |
| WO2022192478A1 (en) | 2021-03-10 | 2022-09-15 | Biohaven Therapeutics Ltd. | Bifunctional degraders of galactose-deficient immunoglobulins |
| AU2022268925A1 (en) | 2021-05-03 | 2023-11-16 | Avilar Therapeutics, Inc. | Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins |
| EP4359430A4 (en) | 2021-06-23 | 2025-07-16 | Lycia Therapeutics Inc | BIFUNCTIONAL COMPOUNDS CONTAINING IGF-2 POLYPEPTIDES |
| US20250127913A1 (en) | 2021-06-24 | 2025-04-24 | Lycia Therapeutics, Inc. | Bifunctional folate receptor binding compounds |
| CN117915956A (zh) | 2021-07-14 | 2024-04-19 | 利西亚治疗公司 | M6pr细胞表面受体结合化合物和缀合物 |
| WO2023009554A1 (en) | 2021-07-26 | 2023-02-02 | Avilar Therapeutics, Inc. | Methods to reduce adverse effects of gene or biologics therapy |
| KR20240099143A (ko) | 2021-08-27 | 2024-06-28 | 예일 유니버시티 | 세포외 단백질의 분자 분해제 |
| WO2023028338A2 (en) | 2021-08-27 | 2023-03-02 | Avilar Therapeutics, Inc. | Mannose 6-phosphate or asgpr receptor binding compounds for the degradation of extracellular proteins |
| WO2023028590A1 (en) | 2021-08-27 | 2023-03-02 | Yale University | Molecular degraders of extracellular proteins |
| JP2025509730A (ja) | 2022-03-15 | 2025-04-11 | イエール ユニバーシティ | 循環タンパク質の選択的分解を目的とした二官能性小分子 |
| EP4611818A2 (en) | 2022-11-03 | 2025-09-10 | Avilar Therapeutics, Inc. | Asgpr-binding heterobifunctional compounds for the degradation of immunoglobulins |
-
2022
- 2022-07-14 JP JP2024501119A patent/JP2024524614A/ja active Pending
- 2022-07-14 AU AU2022310356A patent/AU2022310356A1/en active Pending
- 2022-07-14 EP EP22750971.8A patent/EP4370157A1/en active Pending
- 2022-07-14 KR KR1020247004826A patent/KR20240036604A/ko active Pending
- 2022-07-14 CN CN202280061489.6A patent/CN117957020A/zh active Pending
- 2022-07-14 WO PCT/US2022/037227 patent/WO2023288033A1/en not_active Ceased
- 2022-07-14 CA CA3226269A patent/CA3226269A1/en active Pending
-
2023
- 2023-04-14 US US18/301,025 patent/US12258332B2/en active Active
-
2024
- 2024-12-09 US US18/974,654 patent/US20250101007A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230250091A1 (en) | 2023-08-10 |
| KR20240036604A (ko) | 2024-03-20 |
| CN117957020A (zh) | 2024-04-30 |
| AU2022310356A1 (en) | 2024-01-25 |
| CA3226269A1 (en) | 2023-01-19 |
| US20250101007A1 (en) | 2025-03-27 |
| EP4370157A1 (en) | 2024-05-22 |
| WO2023288033A1 (en) | 2023-01-19 |
| US12258332B2 (en) | 2025-03-25 |
| WO2023288033A8 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12258332B2 (en) | ASGPR cell surface receptor binding compounds and conjugates | |
| US20240335544A1 (en) | M6pr cell surface receptor binding compounds and conjugates | |
| EP4087584A2 (en) | Cell surface receptor binding compounds and conjugates | |
| AU2018269568A1 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| JP2026503463A (ja) | Asgpr結合化合物およびコンジュゲート | |
| WO2022150721A1 (en) | Bifunctional folate receptor binding compounds | |
| JP4722484B2 (ja) | グリセロール誘導体 | |
| TW202406574A (zh) | 一種包含親水性糖結構的配體-藥物偶聯物 | |
| KR20230133289A (ko) | 화합물 또는 이의 염, 및 이들에 의해 얻어지는 항체 | |
| JP2026503461A (ja) | サイクリングリソソーム標的化抗体コンジュゲート | |
| WO2025207934A1 (en) | Lysosomal targeting bifunctional molecules for degradation of thyroid stimulating hormone receptor autoantibodies | |
| JP2025526869A (ja) | アントラサイクリン及びそのコンジュゲート | |
| EP4651903A1 (en) | M6pr binding compounds and conjugates | |
| TW202610689A (zh) | 靶向免疫球蛋白e(ige)之循環溶酶體靶向嵌合體 | |
| CN121866074A (zh) | 用于降解肌肉特异性激酶自身抗体的溶酶体靶向双官能分子 | |
| WO2026065268A1 (en) | Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250714 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250714 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260804 |